Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Inclusion Criteria:

• Waldenstrom's macroglobulinemia
• Treatment with Venetoclax
• Non opposition

Exclusion Criteria: none